ANDE's Chairman of the Board has been one of the most persistent sellers on Nasdaq this spring — and the stock keeps climbing anyway.
The headline story at The Andersons is the unusual persistence of insider selling from the top. Patrick Bowe, Chairman of the Board, has sold shares on at least six separate occasions since mid-March, offloading a combined total worth roughly $3.4 million at prices ranging from $70.30 to $76.67. The selling has not relented even as the stock touched fresh multi-month highs this week, closing at $76.59 on April 28 — up 1.2% on the week and 4.6% over the past month. That a company's chairman continues to sell into strength, days before a Q1 earnings call scheduled for May 5, is the sharpest tension this note has to explain.
Short sellers are not amplifying the caution. Short interest is light at 2.2% of the free float, and it actually fell sharply last week — down 16% over seven days to around 733,000 shares. The drop came after a brief spike in mid-April that briefly pushed the position toward 876,000 shares, but that build has now fully reversed. Cost to borrow is negligible at 0.42%, and the lending pool is far from stressed. Availability is comfortable with the borrow market seeing none of the tightening that typically precedes aggressive short-selling campaigns. The short score of 31.5, in the lower half of the ORTEX universe, reinforces the picture: this is not a stock under pressure from the bear side of the ledger.
Options positioning tells a modestly different story. The put/call ratio has climbed to 0.50 — well above its 20-day average of 0.30 and 1.4 standard deviations above the mean. That makes the current reading the most defensively skewed it has been over the past month. For an illiquid name like ANDE, this kind of elevated PCR often reflects hedging ahead of a binary event rather than a directional bet, and with Q1 results due in less than a week the timing fits. The 52-week PCR range runs from 0.12 to 3.38, so 0.50 is far from extreme — but the shift from a 0.19 baseline through most of April is notable.
The Street has been incrementally constructive but not aggressive. BMO Capital raised its target to $75 in February and holds an Outperform, while Benchmark initiated at Buy with the same $75 target. At a closing price of $76.59, the stock now sits fractionally above the consensus mean target — a reminder that the easy money from analyst re-ratings may already be in the price. Valuation multiples have drifted higher too: the P/E is 14.9, up roughly 0.5 points over the past month, while the P/B has expanded to 1.55. Neither is expensive for a food distribution business, but neither offers a meaningful discount to consensus expectations. Factor scores are a bright spot — the company ranks in the 84th percentile for EPS surprise and forward EPS growth, and a standout 99th percentile dividend score, though the dividend data in hand is stale and should be verified independently before being traded on.
Earnings history adds context without clarity. The last two Q1 prints, in February 2026, both produced negative one-day reactions of around 3-6%, and five-day returns were similarly negative. That is a consistent pattern of post-print weakness, even in quarters where the underlying numbers were acceptable. Victory Capital built a new position of 570,000 shares in the most recent filing period, while Rubric Capital and Ophir Asset Management each appear as new entrants in the institutional register. That buying sits alongside Bowe's selling — a divergence between the institutional base adding exposure and the company's own chairman trimming.
What to watch: whether the Chairman's pre-earnings sales prove to be routine tax-planning liquidations or something more informative will become clearer once the May 5 Q1 call prints.
See the live data behind this article on ORTEX.
Open ANDE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
